知镜 Cognispect · 医学文献与研究工作台

Adverse Events and Safety Outcomes Associated With Chemotherapy for Inflammatory Bowel Disease-associated Gastrointestinal Cancers.

Hasegawa N, Ogino T, Sekido Y, Takeda M, Hata T, Hamabe A, Miyoshi N, Uemura M, Eguchi H, Doki Y.
Anticancer research · 2026-04-01 · PMID 41895756

文献摘要

Background/aim Management of inflammatory bowel disease-associated gastrointestinal cancers, including Crohn's disease-associated cancer and ulcerative colitis-associated cancer, remains challenging because of concerns regarding treatment-related toxicity and limited clinical data. We aimed to investigate the safety of chemotherapy in patients with inflammatory bowel disease-associated gastrointestinal cancer. Patients and methods This retrospective study analyzed 21 patients with inflammatory bowel disease-associated gastrointestinal cancer (Crohn's disease-associated cancer: 10; ulcerative colitis-associated cancer: 11) who received chemotherapy or chemoradiotherapy between 2010 and 2024. Chemotherapy regimens, adverse events, treatment completion rates, and residual small intestinal lengths in patients with Crohn's disease were evaluated. Results Oxaliplatin-based chemotherapy was the most commonly used chemotherapeutic regimen. Dose reduction was required in all patients with Crohn's disease-associated cancer and in 64% of those with ulcerative colitis-associated cancer, primarily because of diarrhea or neurotoxicity. In the Crohn's disease-associated cancer group, diarrhea occurred in all patients and was significantly more severe in those with shorter residual small intestines ( p =0.02). Despite these toxicities, 80% of patients with Crohn's disease-associated cancer and 55% of those with ulcerative colitis-associated cancer completed the planned chemotherapy regimen. No inflammatory bowel disease flares or need for corticosteroids or biologics occurred during treatment. Chemoradiotherapy was administered to five patients with Crohn's disease-associated cancer and locally advanced anorectal cancer, with no major safety concerns. Conclusion Chemotherapy, including chemoradiotherapy, can be safely administered to patients with inflammatory bowel disease-associated gastrointestinal cancer with careful management. In Crohn's disease-associated cancer, residual small intestinal length is a key factor in predicting gastrointestinal toxicity severity, particularly diarrhea. Individualized dose adjustments and close monitoring are essential to balance cancer treatment efficacy with the unique risks associated with inflammatory bowel disease.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。